Interferon-beta  	Interferon-beta  	 NNP	B-NP
and  	and  	 CC	O
disability  	disability  	 JJ	B-NP
progression  	progression  	 NN	I-NP
in  	in  	 IN	O
relapsing-remitting  	relapsing-remitting  	 JJ	O
multiple  	multiple  	 JJ	O
sclerosis  	sclerosis  	 NN	O
To  	To  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
impact  	impact  	 NN	O
of  	of  	 IN	O
interferon  	interferon  	 NNS	B-NP
( 	( 	 -LRB-	O
IFN 	IFN 	 NNP	B-NP
) 	) 	 -RRB-	O
-beta  	-beta  	 JJ	O
treatment  	treatment  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
progression  	progression  	 NN	O
of  	of  	 IN	O
unremitting  	unremitting  	 JJ	O
disability  	disability  	 NN	O
in  	in  	 IN	O
IFN-beta  	IFN-beta  	 JJ	B-NP
treated  	treated  	 NN	I-NP
and  	and  	 CC	O
untreated  	untreated  	 JJ	O
relapsing-remitting  	relapsing-remitting  	 NN	B-NP
( 	( 	 -LRB-	O
RR 	RR 	 NNP	B-NP
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
multiple  	multiple  	 JJ	B-NP
sclerosis  	sclerosis  	 NNS	I-NP
( 	( 	 -LRB-	O
MS 	MS 	 NNP	B-NP
)  	)  	 -RRB-	O
using  	using  	 VBG	O
prospective  	prospective  	 JJ	B-NP
cohort  	cohort  	 JJ	I-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
cohort  	cohort  	 NN	B-NP
of  	of  	 IN	O
419  	419  	 CD	O
RRMS  	RRMS  	 NNP	B-NP
( 	( 	 -LRB-	O
236  	236  	 CD	O
IFN-beta-treated  	IFN-beta-treated  	 JJ	B-NP
and  	and  	 CC	O
183  	183  	 CD	O
untreated 	untreated 	 CD	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
was  	was  	 VBD	O
followed  	followed  	 VBN	O
for  	for  	 IN	O
up  	up  	 RB	O
to  	to  	 TO	O
7  	7  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
Cox  	Cox  	 NNP	B-NP
proportional  	proportional  	 JJ	I-NP
hazards  	hazards  	 NNS	I-NP
regression  	regression  	 JJ	O
models  	models  	 NNS	O
adjusted  	adjusted  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
relapses  	relapses  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
year  	year  	 NN	O
before  	before  	 IN	O
first  	first  	 JJ	O
visit  	visit  	 NN	O
was  	was  	 VBD	O
used  	used  	 VBN	O
to  	to  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
differences  	differences  	 NNS	O
between  	between  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
groups  	groups  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
three  	three  	 CD	O
end  	end  	 NN	B-NP
points 	points 	 NNS	I-NP
:  	:  	 :	O
secondary  	secondary  	 JJ	B-NP
progression  	progression  	 NNS	I-NP
( 	( 	 -LRB-	O
SP 	SP 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
sustained  	sustained  	 VBD	O
Expanded  	Expanded  	 NNP	B-NP
Disability  	Disability  	 NNP	I-NP
Status  	Status  	 NNP	I-NP
Scale  	Scale  	 NNP	I-NP
( 	( 	 -LRB-	O
EDSS 	EDSS 	 NNP	B-NP
)  	)  	 -RRB-	O
score  	score  	 VBP	O
4  	4  	 CD	O
and  	and  	 CC	O
6 	6 	 CD	O
.  	.  	 .	O
Time  	Time  	 NN	O
from  	from  	 IN	O
disease  	disease  	 NN	B-NP
onset  	onset  	 NN	I-NP
was  	was  	 VBD	O
used  	used  	 VBN	O
as  	as  	 IN	O
survival  	survival  	 NN	B-NP
time  	time  	 NN	I-NP
variable 	variable 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
IFN-beta-treated  	IFN-beta-treated  	 JJ	B-NP
group  	group  	 NN	I-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
highly  	highly  	 RB	O
significant  	significant  	 JJ	O
reduction  	reduction  	 NN	O
( 	( 	 -LRB-	O
hazard  	hazard  	 NN	B-NP
ratio  	ratio  	 NN	I-NP
[ 	[ 	 -LRB-	O
HR 	HR 	 NNP	B-NP
] 	] 	 -RRB-	O
,  	,  	 ,	O
0.34 	0.34 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 NNS	I-NP
[ 	[ 	 -LRB-	O
CI 	CI 	 NNP	B-NP
]  	]  	 -RRB-	O
0.19-0.61 	0.19-0.61 	 NNP	O
,  	,  	 ,	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.001 	0.001 	 CD	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
SP  	SP  	 NNP	B-NP
when  	when  	 WRB	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
untreated  	untreated  	 JJ	O
patients 	patients 	 NNS	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
favor  	favor  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
IFN-beta-treated  	IFN-beta-treated  	 JJ	B-NP
group  	group  	 NN	I-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
end  	end  	 NN	I-NP
point  	point  	 NN	I-NP
EDSS  	EDSS  	 NNP	I-NP
score  	score  	 NN	I-NP
of  	of  	 IN	O
4  	4  	 CD	O
( 	( 	 -LRB-	O
HR=0.45 	HR=0.45 	 NNP	B-NP
,  	,  	 ,	O
95 	95 	 CD	O
% 	% 	 NN	O
CI  	CI  	 NNP	O
0.28-0.73 	0.28-0.73 	 NNP	O
,  	,  	 ,	O
p=0.001 	p=0.001 	 CD	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
EDSS  	EDSS  	 NNP	B-NP
score  	score  	 NN	I-NP
of  	of  	 IN	O
6  	6  	 CD	O
( 	( 	 -LRB-	O
HR=0.34 	HR=0.34 	 NNP	B-NP
,  	,  	 ,	O
95 	95 	 CD	O
% 	% 	 NN	O
CI  	CI  	 NNP	O
0.16-0.75 	0.16-0.75 	 NNP	O
,  	,  	 ,	O
p=0.007 	p=0.007 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
observational  	observational  	 JJ	B-NP
study  	study  	 NN	I-NP
further  	further  	 RB	O
supports  	supports  	 VBZ	O
the  	the  	 DT	O
notion  	notion  	 NN	O
that  	that  	 IN	O
IFN-beta  	IFN-beta  	 NNP	B-NP
could  	could  	 MD	O
have  	have  	 VB	O
potential  	potential  	 JJ	O
beneficial  	beneficial  	 JJ	O
effect  	effect  	 NN	O
on  	on  	 IN	O
disease  	disease  	 NN	B-NP
progression  	progression  	 NN	I-NP
in  	in  	 IN	O
RRMS 	RRMS 	 NNP	B-NP
.  	.  	 .	O
